Bayer agreed to acquire unlisted U.S. biotech firm Asklepios BioPharmaceutical Inc for as much as $4 billion in a bet on gene therapy with the help of modified viruses.
The drug will now progress to pivotal Phase III trials after demonstrating trends towards a disease-modifying impact.
Bayer hopes to release its new knockdown herbicide, icafolin-methyl, in Australia in 2028, subject to APVMA approvals and ...
BAYRY's subsidiary BlueRock reports 36-month data showing its Parkinson's therapy bemdaneprocel remains safe and effective in ...
Reports vary on how close Steven Gerrard is to being appointed Rangers boss, while Besiktas are reportedly interested in ...
TipRanks on MSN
Regeneron and Bayer Complete Long-term Study on Retinopathy of Prematurity Treatments
Regeneron Pharmaceuticals (($REGN)) announced an update on their ongoing clinical study. Study Overview: Regeneron Pharmaceuticals, in ...
TipRanks on MSN
Oracle Commodity Holding Corp. Appoints New VP Legal and Announces Leadership Changes
Oracle Commodity Holding Corp. ( ($TSE:ORCL) ) has provided an update. Oracle Commodity Holding Corp. has appointed Stephanie Lee as Vice ...
Bangkok Post on MSN
Bayer Spotlights Innovations to Address Rising Health Challenges in the Asia Pacific Region
Bayer reinforced its commitment to advancing healthcare solutions for patients in the APAC region with very diverse ...
It's a test of CEO Bill Anderson's development credentials as patent expiries on blockbuster drugs threaten the group's ...
The Duchenne Muscular Dystrophy Drugs Market presents opportunities in advanced genetic therapies, digital health, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback